Drugs / Δ9-THC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07346690 | Feb 2026 → Feb 2028 expected | — | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05272865 | Aug 2023 → Feb 2024 | chemotherapy-induced toxicity, neoplasm | LaSanta S A S | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Δ9-THC | “Pharmacokinetic and Pharmacodynamic Evaluation of 3 Standard Formulations of Δ9-THC in Healthy Volunteers and Post-chemotherapy Patients in Colombia” NCT05272865 ↗1“AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.” NCT07346690 ↗ |
| Known as | THC | “Drug: THC Oral solution of THC (5 mg/mL)” NCT05272865 ↗ |
| Route | Oral | “Oral solution of THC” NCT05272865 ↗ |